Applying biopharma rigor to the vast
therapeutic potential of the endocannabinoid system

Modulating the endocannabinoid system is among the most promising fields in the pharmaceutical industry. At Artelo Biosciences®, we’re applying true biopharma discipline toward developing and commercializing a diverse portfolio of novel therapeutic candidates targeting the endocannabinoid system.

How we’re delivering on the promise of the endocannabinoid system (ECS)

Understanding the science

We believe a biopharma approach will lead to novel and high-impact therapeutics which harness the full potential of the ECS

A portfolio-based strategy

Our diverse set of programs are focused on a broad portfolio of assets with three distinct mechanisms to modulate the ECS

Our proven leadership team

We have decades of experience in biopharmaceutical development, commercialization, and ECS science